Douglas M Choo1, Jai Jai Shiva Shankar2. 1. Department of Diagnostic Imaging, Division of Neuroradiology, QE II Health Sciences Centre, Canada. 2. Department of Diagnostic Imaging, Division of Neuroradiology, QE II Health Sciences Centre, Canada shivajai1@gmail.com.
Abstract
BACKGROUND AND PURPOSE: Intracranial dural arteriovenous fistulas (DAVFs) with cortical venous drainage have significant morbidity and mortality. Complete closure of these lesions is necessary to reduce these risks. The purpose of our study was to compare the outcome of DAVFs treated with Onyx versus those treated with n-Butyl Cyanoacrylate (nBCA) and coil embolization in a case-control study. Compared with nBCA and coil embolization, we hypothesized that Onyx embolization for DAVF is safer and has a higher chance of complete obliteration, with no need for post-embolization surgery for the DAVF. MATERIALS AND METHODS: From 1998 to 2015, 29 patients who had DAVFs were treated with endovascular embolization. Of these, 24 patients had imaging available for analysis. Successful closure rates, complications, and procedure time were compared between the embolization techniques. RESULTS: The chance of not requiring post-embolization surgery with Onyx (81.8%) was significantly higher (p = 0.005) than with nBCA (22.22%). The complication rate with Onyx (9.1%) tended to be lower compared with that of nBCA (22.22%; p = 0.37). Procedural time was not significantly different between Onyx (mean 267 minutes) and nBCA (mean 288 minutes) (p = 0.59). The odds ratio of a DAVF being treated with Onyx and then requiring no follow-up surgery was 17.5 (95% CI 1.97-155.4). CONCLUSION: Our case-control study suggests that Onyx embolization is superior to nBCA and coil embolization in completely obliterating DAVFs, with higher odds of no post-embolization surgery. We also found that Onyx is safe for embolization of DAVFs, with no associated neurological mortality and morbidity.
BACKGROUND AND PURPOSE:Intracranial dural arteriovenous fistulas (DAVFs) with cortical venous drainage have significant morbidity and mortality. Complete closure of these lesions is necessary to reduce these risks. The purpose of our study was to compare the outcome of DAVFs treated with Onyx versus those treated with n-Butyl Cyanoacrylate (nBCA) and coil embolization in a case-control study. Compared with nBCA and coil embolization, we hypothesized that Onyx embolization for DAVF is safer and has a higher chance of complete obliteration, with no need for post-embolization surgery for the DAVF. MATERIALS AND METHODS: From 1998 to 2015, 29 patients who had DAVFs were treated with endovascular embolization. Of these, 24 patients had imaging available for analysis. Successful closure rates, complications, and procedure time were compared between the embolization techniques. RESULTS: The chance of not requiring post-embolization surgery with Onyx (81.8%) was significantly higher (p = 0.005) than with nBCA (22.22%). The complication rate with Onyx (9.1%) tended to be lower compared with that of nBCA (22.22%; p = 0.37). Procedural time was not significantly different between Onyx (mean 267 minutes) and nBCA (mean 288 minutes) (p = 0.59). The odds ratio of a DAVF being treated with Onyx and then requiring no follow-up surgery was 17.5 (95% CI 1.97-155.4). CONCLUSION: Our case-control study suggests that Onyx embolization is superior to nBCA and coil embolization in completely obliterating DAVFs, with higher odds of no post-embolization surgery. We also found that Onyx is safe for embolization of DAVFs, with no associated neurological mortality and morbidity.
Authors: T G Abud; A Nguyen; J P Saint-Maurice; D G Abud; D Bresson; L Chiumarulo; E Enesi; E Houdart Journal: AJNR Am J Neuroradiol Date: 2011-09-29 Impact factor: 3.825
Authors: James David Rabinov; Albert J Yoo; Christopher S Ogilvy; Bob S Carter; Joshua A Hirsch Journal: J Neurointerv Surg Date: 2012-05-01 Impact factor: 5.836
Authors: Pierre Guedin; Stephan Gaillard; Anne Boulin; Stephanie Condette-Auliac; Frederic Bourdain; Stephanie Guieu; Michel Dupuy; Georges Rodesch Journal: J Neurosurg Date: 2010-03 Impact factor: 5.115
Authors: Yin C Hu; C Benjamin Newman; Shervin R Dashti; Felipe C Albuquerque; Cameron G McDougall Journal: J Neurointerv Surg Date: 2011-01-06 Impact factor: 5.836
Authors: Thiago G Abud; Emmanuel Houdart; Jean-Pierre Saint-Maurice; Daniel G Abud; Carlos E Baccin; Andrew D Nguyen; Nitamar Abdala Journal: Clin Neuroradiol Date: 2017-08-11 Impact factor: 3.649
Authors: Alan Mendez-Ruiz; Waldo R Guerrero; Viktor Szeder; Mudassir Farooqui; Cynthia B Zevallos; Darko Quispe-Orozco; Santiago Ortega-Gutierrez Journal: Interv Neuroradiol Date: 2021-09-13 Impact factor: 1.764
Authors: Mohammed A Azab; Emma R Dioso; Matthew C Findlay; Jayson Nelson; Cameron A Rawanduzy; Philip Johansen; Brandon Lucke-Wold Journal: J Rare Dis Orphan Drugs Date: 2022-06-07
Authors: H G Kortman; G Bloemsma; I Boukrab; J P Peluso; M Sluzewski; B van der Pol; G N Beute; C B Majoie; W J van Rooij Journal: Interv Neuroradiol Date: 2017-10-04 Impact factor: 1.610